SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents.
about
Chloride channels as drug targets.Dyssynergic defecation and biofeedback therapyOpioid-induced constipation: advances and clinical guidanceBrain-gut axis: from basic understanding to treatment of IBS and related disordersCurrent developments in pharmacological therapeutics for chronic constipationTreatment for constipation: new and old pharmacological strategiesClC-2 regulation of intestinal barrier function: Translation of basic science to therapeutic targetCellular mechanisms underlying the laxative effect of flavonol naringenin on rat constipation modelLubiprostone stimulates duodenal bicarbonate secretion in ratsHEK-293 cells expressing the cystic fibrosis transmembrane conductance regulator (CFTR): a model for studying regulation of Cl- transport.Review article: the treatment of functional abdominal bloating and distension.Persistent constipation and abdominal adverse events with newer treatments for constipation.Epac1 mediates protein kinase A-independent mechanism of forskolin-activated intestinal chloride secretion.Lubiprostone ameliorates the cystic fibrosis mouse intestinal phenotype.Lubiprostone improves visualization of small bowel for capsule endoscopy: a double-blind, placebo-controlled 2-way crossover studyNew horizons in the treatment of cystic fibrosis.Research and progress on ClC‑2 (Review).Luminally Acting Agents for Constipation Treatment: A Review Based on Literatures and Patents.Review article: new receptor targets for medical therapy in irritable bowel syndromeLubiprostone reverses the inhibitory action of morphine on intestinal secretion in guinea pig and mouse.Update on the management of constipation in the elderly: new treatment optionsContrasting effects of linaclotide and lubiprostone on restitution of epithelial cell barrier properties and cellular homeostasis after exposure to cell stressors.Lubiprostone: evaluation of the newest medication for the treatment of adult women with constipation-predominant irritable bowel syndromeThe treatment of irritable bowel syndromeCLC channel function and dysfunction in health and disease.Lubiprostone stimulates small intestinal mucin release.Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents.Treatment of Chronic Constipation: Prescription Medications and Surgical Therapies.Lubiprostone targets prostanoid EP₄ receptors in ovine airways.Lubiprostone vs Senna in postoperative orthopedic surgery patients with opioid-induced constipation: a double-blind, active-comparator trial.Ion channel pharmacology.Lubiprostone decreases the small bowel transit time by capsule endoscopy: an exploratory, randomised, double-blind, placebo-controlled 3-way crossover study.Lubiprostone in constipation: clinical evidence and place in therapy.Long-term safety and effectiveness of lubiprostone, a chloride channel (ClC-2) activator, in patients with chronic idiopathic constipationDiagnosis and treatment of chronic constipation--a European perspective.Lubiprostone does not influence visceral pain thresholds in patients with irritable bowel syndromeDirect interactions between ENaC gamma subunit and ClCN2 in cystic fibrosis epithelial cells.Optimal management of constipation associated with irritable bowel syndromeProkinetic effects of large-dose lubiprostone on gastrointestinal transit in dogs and its mechanismsA comparison of linaclotide and lubiprostone dosing regimens on ion transport responses in human colonic mucosa
P2860
Q24601830-C12CE086-98BF-4236-98EB-CDD58EB48158Q24646884-7EE1C0EF-00AF-4596-AAC8-A3E69CFABCD8Q26765571-D28B8AE3-B009-4AAD-B74E-F8313ED3B007Q27024801-2C17E518-912D-42D1-B11F-A6CF395499A1Q27025474-38999FD5-49AC-4817-BF43-CCD30EDB58F4Q27027346-077BDA90-D668-49A3-8BD9-7C15B6F08615Q28066092-FF3F6E7A-2A99-457E-A5E8-280A180ADCA8Q28473690-FF98B41A-CA4B-412F-B17C-13F022302468Q28572915-C86FBA55-D25B-4F75-9BF3-8BD9D4AEF696Q30609337-0B1BB664-9D36-4F48-90BF-D6AFDB97D667Q33450132-95829345-52B4-4C5A-9D57-837D72FBCA4FQ33468562-CD98B8CE-7667-4222-9A90-7A04B503C233Q33590300-64B20F4D-94CC-4200-AE7D-F5C8FF673049Q33693282-7FAD987F-2BD2-4D3F-A710-688F928141A6Q33746598-5CECFC8E-9651-430D-B7C1-84F0ECCC9FB4Q33756002-2A71C604-42FF-43D7-AB42-472731918BAFQ33828111-6412E082-87F8-41F0-BB3A-EAC02BFFD126Q33854983-961244FB-9654-426A-A2AD-A9A15F4CBA42Q33959307-FE27194E-9292-4A2B-A3C1-CB8A039FEC9FQ34028142-2B893932-E81A-4B1E-A405-758E8412C8B1Q34060462-27845D4D-493F-40DD-9681-5C40FB64D524Q34254749-D81B61E3-6327-4839-BAA9-7F42988AB659Q34345704-A7BA0DC2-B264-483A-B1A3-10936C2316E0Q34409009-FB85F62D-F692-4EA7-BE4B-A15628A79568Q34444580-FC07C613-1FA3-4508-BDD0-40C17F5D5D4BQ34468167-E74F213E-09AD-41B4-B1CC-B7A4AC409F93Q34478089-3BB62BFB-9D18-4984-B2ED-134EB9949113Q34522966-A4298D8A-C68F-4614-9412-E7410EDD8FE3Q34540238-36C94552-CC5E-4738-8CBF-846BA297E01EQ34552212-23B16E15-60FF-4AB2-A8FE-B784A4EC7953Q34613758-59D8B62E-11AB-4D64-A0AB-CDB7E6D559CDQ34966504-FDD6EC9A-B2CD-48A5-9950-9C18D5C43958Q35091370-0B4DE6D2-8F3E-4456-BDAB-8C8974838367Q35204780-D1013853-4816-482B-8084-52C2FC9A639BQ35207439-B9FED4B2-4CF0-45EB-BF9C-970ED5F1A702Q35251195-EC1811F5-9641-4955-A1D2-5F77C6C8DB75Q35294275-E0C230D7-0876-463F-AF21-4212A5A31294Q35586543-74A676BA-B9D3-4EA4-94D6-8A61837E8538Q35662982-04DA1E0C-1ABA-4924-9C66-D2D06EE1C792Q35664952-86324B0B-A25D-4E3F-8BA5-012D82C3ABF1
P2860
SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
SPI-0211 activates T84 cell ch ...... human ClC-2 chloride currents.
@en
type
label
SPI-0211 activates T84 cell ch ...... human ClC-2 chloride currents.
@en
prefLabel
SPI-0211 activates T84 cell ch ...... human ClC-2 chloride currents.
@en
P2093
P1476
SPI-0211 activates T84 cell ch ...... human ClC-2 chloride currents.
@en
P2093
Ann M Sherry
Danuta H Malinowska
John Cuppoletti
Kirti P Tewari
Myra L Patchen
Ryuji Ueno
P304
P356
10.1152/AJPCELL.00528.2003
P577
2004-06-22T00:00:00Z